Enhancement potential of sucrose laurate (L-1695) on intestinal absorption of water-soluble high molecular weight compounds

Current Drug Delivery

Volumn 9, Issue 5, 2012, Pages 487-494

  Onishi, Hiraku ^a   Imura, Yu ^a   Uchida, Minoru ^b   Machida, Yoshiharu ^a  

^a HOSHI UNIVERSITY   (Japan)

^b MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

Fluorescein isothiocyanate labeled dextran; Intestinal absorption enhancement; Non loop method; Sucrose fatty acid ester; Sucrose laurate

Indexed keywords

ACETYLCYSTEINE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; REBAMIPIDE; SUCROSE ESTER DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SOLUBILITY; INTESTINE ABSORPTION; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DEXTRANS; ESTERS; FATTY ACIDS; FLUORESCEIN-5-ISOTHIOCYANATE; INTESTINAL ABSORPTION; MALE; MOLECULAR WEIGHT; RATS; RATS, WISTAR; SOLUBILITY; SUCROSE; WATER;

EID: 84866995927     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112802650699     Document Type: Article

References (42)

1. Li, M.; Shen, Y.; Burton, K.W.; DeLuca P.P.; Mehta, R.C.; Baumann, B.D.; Wronski, T.J. A comparison of the skeletal effects of intermittent and continuous administration of calcitonin in ovariectomized rats. Bone, 1996, 18(4), 375-380.
2. Søeborg, T.; Rasmussen, C.H.; Mosekilde, E.; Colding-Jørgensen, M. Bioavailability and variability of biphasic insulin mixtures. Eur. J. Pharm. Sci., 2011, in press.
3. Wray, S.; Armstrong, R.; Herrman, C.; Calkwood, J.; Cascione, M.; Watsky, E.; Hayward, B.; Mercer, B.; Dangond, F. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study. Expert Opin. Drug Deliv., 2011, 8(12),1543-1553.
4. Malik, D.K.; Baboota, S.; Ahuja, A.; Hasan, S.; Ali, J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv., 2007, 4(2), 141-151.
5. Passey, C.; Bhardwaj, S.P.; Majumdar, D.K. Is relief from diabetes just a breath away? Curr. Drug Deliv., 2009, 6(2), 166-173.
6. Wong, T.W. Design of oral insulin delivery systems. J. Drug Target., 2010, 18(2), 79-92.
7. Foldvari, M.; Badea, I.; Kumar, P.; Wettig, S.; Batta, R.; King, M.J.; He, Z.; Yeboah, E.; Gaspar, K.; Hull, P.; Shear, N.H. Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections. Curr. Drug Deliv., 2011, 8(3), 307-319.
8. Yamamoto, A.; Taniguchi, T.; Rikyuu, K.; Tsuji, T.; Fujita, T.; Murakami, M.; Muranishi, S. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res., 1994, 11(10), 1496-1500.
9. Larhed, A.W.; Artursson, P.; Gråsjö, J.; Björk E. Diffusion of drugs in native and purified gastrointestinal mucus. J. Pharm. Sci., 1997, 86(6), 660-665.
10. Shimizu, H. Development of an enteric-coated lactoferrin tablet and its application. Biometals, 2004, 17(3), 343-347.
11. Takatsuka, S.; Kitazawa, T.; Morita, T.; Horikiri, Y.; Yoshino, H. Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and nonionic surfactant. Eur. J. Pharm. Biopharm., 2006, 62(1), 52-58.
12. Di Colo, G.; Zambito, Y.; Zaino, C. Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetrationenhancing properties, mechanism of action, safety issues. J. Pharm. Sci., 2008, 97(5), 1652-1680.
13. Takeuchi, T.; Jyonotsuka, T.; Kamemori, N.; Kawano, G.; Shimizu, H.; Ando, K.; Harada, E. Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp. Physiol., 2006, 91(6), 1033-1040.
14. Kawashima, Y.; Yamamoto, H.; Takeuchi, H., Kuno, Y. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol., 2000, 5(1), 77-85.
15. Takatsuka, S.; Morita, T.; Horikiri, Y., Yamahara, H.; Saji, H. Influence of various combinations of mucolytic agent and nonionic surfactant on intestinal absorption of poorly absorbed hydrophilic compounds. Int. J. Pharm., 2008, 349(1-2), 94-100.
16. Chetty, D.J.; Chien, Y.W. Novel methods of insulin delivery: an update. Crit. Rev. Ther. Drug Carrier Syst., 1998, 15(6), 629-670.
17. Maher, S.; Leonard, T.W.; Jacobsen, J.; Brayden, D.J. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev., 2009, 61(15), 1427-1449.
18. Swenson, E.S.; Milisen, W.B.; Curatolo, W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm. Res., 1994, 11(8), 1132-1142.
19. Sharma, P.; Varma, M.V.; Chawla, H.P.; Panchagnula, R. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies. FARMACO, 2005, 60(11-12), 874-883.
20. Mitsubishi-Kagaku Food Corp., "Ryoto Sugar Ester ", Mitsubishi-Kagaku Food Corp., Tokyo, 2006.
21. Ayala-Bravo, H.A.; Quintanar-Guerrero, D.; Naik, A.; Kalia, Y.N.; Cornejo-Bravo, J.M.; Ganem-Quintanar. A. Effects of sucrose oleate and sucrose laureate on in vivo human stratum corneum permeability. Pharm Res., 2003, 20(8), 1267-1273.
22. Okamoto, H.; Sakai, T.; Danjo, K. Effect of sucrose fatty acid esters on transdermal permeation of lidocaine and ketoprofen. Biol. Pharm. Bull., 2005, 28(9), 1689-1694.
23. Taki, K.; Machida, K.; Katayama, K. Elastase-containing composition permitting elastase to be absorbed in increased amount. U.S. Patent 4,397,951, Aug 9, 1983.
24. Nakada, Y.; Awata, N.; Nakamichi, C.; Sugimoto I. The effect of additives on the oral mucosal absorption of human calcitonin in rats. J. Pharmacobiodyn., 1988, 11(6), 395-401.
25. Sasaki, I.; Tozaki, H.; Matsumoto, K.; Ito, Y.; Fujita, T.; Murakami, M.; Muranishi, S.; Yamamoto, A. Development of an oral formulation of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, using n-lauryl-D-maltopyranoside as an absorption enhancer. Biol. Pharm. Bull., 1999, 22(6), 611-615.
26. Kotzé, A.F.; Luessen, H.L.; de Leeuw, B.J.; de Boer, B.G.; Verhoef, J.C.; Junginger, H.E. N-Trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm. Res., 1997, 14(9), 1197-1202.
27. Cao, D.; Kitamura, T.; Todo, H.; Yoo, S.D.; Sugibayashi K. Pretreatment effects of moxibustion on the skin permeation of FITC-dextran. Int. J. Pharm., 2008, 354(1-2), 117-125.
28. Gao, Y.; He, L.; Katsumi, H.; Sakane, T.; Fujita, T.; Yamamoto, A. Improvement of intestinal absorption of water-soluble macromolecules by various polyamines: intestinal mucosal toxicity and absorption-enhancing mechanism of spermine. Int. J. Pharm., 2008, 354(1-2), 126-134.
29. Gao, Y.; He, L.; Katsumi, H.; Sakane, T.; Fujita, T.; Yamamoto, A. Improvement of intestinal absorption of insulin and water-soluble macromolecular compounds by chitosan oligomers in rats. Int. J. Pharm., 2008, 359(1-2), 70-78.
30. Schröder, U.; Arfors, K.E.; Tangen, O. Stability of fluorescein labeled dextrans in vivo and in vitro. Microvasc Res., 1976, 11(1), 57-66.
31. New updated data of FITC-Dextran, Tdb ConsultancyAB (Uppsala).http://www.tdbcons.se/fitcdextran/ (2010).
32. Sakai, M.; Imai, T.; Ohtake, H.; Azuma, H.; Otagiri, M. Effects of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: assessment by confocal laser scanning microscopy. J. Pharm. Sci., 1997, 86(7), 779-785.
33. Kondoh, M.; Fujii, M.; Yagi, K.; Watanabe, Y. Barriology-based strategy for drug absorption. Yakugaku Zasshi, 2007, 127(4), 601-609.
34. Sadeghi, A.M.; Dorkoosh, F.A.; Avadi, M.R.; Weinhold, M.; Bayat, A.; Delie, F.; Gurny, R.; Larijani, B.; Rafiee-Tehrani, M.; Junginger, H.E. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm., 2008, 70(1), 270-278.
35. Yamaoka, K.; Tanigawara, Y.; Nakagawa, T.; Uno, T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn., 1981, 4(11), 879-885.
36. Duizer, E.; Gilde, A.J.; Versantvoort, C.H.; Groten, J.P. Effects of cadmium chloride on the paracellular barrier function of intestinal epithelial cell lines. Toxicol. Appl. Pharmacol., 1999, 155(2), 117-126.
37. Kamm, W.; Jonczyk, A.; Jung, T.; Luckenbach, G.; Raddatz, P.; Kissel, T. Evaluation of absorption enhancement for a potent cyclopeptidic alpha(nu)beta(3)-antagonist in a human intestinal cell line (Caco-2). Eur. J. Pharm. Sci., 2000, 10(3), 205-214.
38. Brown, J.R.; Collett, J.H.; Attwood, D.; Ley, R.W.; Sims, E.E. Influence of monocaprin on the permeability of a diacidic drug BTA-243 across Caco-2 cell monolayers and everted gut sacs. Int. J. Pharm., 2002, 245(1-2), 133-142.
39. Boulmedarat, L.; Bochot, A.; Lesieur, S.; Fattal, E. Evaluation of buccal methyl-beta-cyclodextrin toxicity on human oral epithelial cell culture model. J. Pharm. Sci., 2005, 94(6), 1300-1309.
40. Tirumalasetty, P.P.; Eley, J.G. Permeability enhancing effects of the alkylglycoside, octylglucoside, on insulin permeation across epithelial membrane in vitro. J. Pharm. Pharm. Sci., 2006, 9(1), 32-39.
41. Yamamoto, A. Improvement of transmucosal absorption of biologically active peptide drugs. Yakugaku Zasshi, 2001, 121(12), 929-948.
42. Namani, T.; Walde, P. From decanoate micelles to decanoic acid/dodecylbenzenesulfonate vesicles. Langmuir, 2005, 21(14), 6210-6219.